Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Add To Watchlist

Recent & Breaking News (NDAQ:AZN)

The Market In 5 Minutes: Apple Issues Apology, Softbank & Uber, The Year In Cryptos

Benzinga.com December 29, 2017

A Peek Into The Markets: U.S. Stock Futures Surge On Last Trading Day Of 2017

Benzinga.com December 29, 2017

US FDA Updates SYMBICORT Label with LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related Outcomes

Business Wire December 21, 2017

US FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

Business Wire December 18, 2017

AstraZeneca’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials

Business Wire December 10, 2017

AstraZeneca’s CALQUENCE® (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial

Business Wire December 9, 2017

AstraZeneca to Highlight Its Commitment to Blood Cancers at the 2017 American Society of Hematology Annual Meeting

Business Wire December 6, 2017

Celebrity Trainer and Author Bob Harper Teams up with AstraZeneca to Connect with Fellow Heart Attack Survivors

Business Wire November 30, 2017

FASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib

Business Wire November 15, 2017

FASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic Asthma

PR Newswire November 14, 2017

AstraZeneca Shares Scientific Updates from Its Extensive Cardiovascular, Renal and Metabolic Diseases (CVMD) Portfolio at AHA 2017

Business Wire November 8, 2017

Here's What Was Intriguing About Incyte's Q3 Report

Benzinga.com November 1, 2017

US FDA Approves New Easy-to-Use, Once-Weekly BYDUREON® BCise™ Injectable Medicine for Patients with Type-2 Diabetes

Business Wire October 23, 2017

AstraZeneca Announces New Data Showing US Preterm Infants at Significantly Greater Risk of RSV Hospitalizations Following 2014 Guidance Change

Business Wire October 18, 2017

US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

Business Wire October 18, 2017

US FDA Accepts Supplemental Biologics License Application for IMFINZI® (durvalumab) in Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Business Wire October 17, 2017

Watch These 8 Huge Call Purchases In Tuesday Trade

Benzinga.com October 10, 2017

TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation by US FDA for the 1st-Line Treatment of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

Business Wire October 9, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com September 22, 2017

The Market In 5 Minutes

Benzinga.com September 22, 2017